Mammalian Segment to Dominate Asia-Pacific Biopharmaceutical Contract Manufacturing Market during 2019–2028

According to a new market research study on “Asia-Pacific Biopharmaceutical Contract Manufacturing Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product, Service, and Source,” is expected to reach US$ 5,462.23 million by 2028 from US$ 2,973.92 million in 2021. The market is estimated to grow at a CAGR of 9.1% from 2021 to 2028. Emerging markets is the major factor driving the growth of the Asia-Pacific biopharmaceutical contract manufacturing market. However, growing competition in industry may hinder the growth of Asia-Pacific biopharmaceutical contract manufacturing market. The report provides trends prevailing in the Asia-Pacific biopharmaceutical contract manufacturing market along with the drivers and restraints pertaining to the market growth.

The Asia-Pacific biopharmaceutical contract manufacturing market is segmented into product, service, source, and country. The Asia-Pacific biopharmaceuticals contract manufacturing market, by product, is segmented into biologics and biosimilar. The biologics segment held the largest share of the market in 2020. Based on biologics the market is further segmented into monoclonal antibodies , recombinant proteins , vaccines , and others. In 2020, the monoclonal antibodies segment held the largest share Asia-Pacific biopharmaceutical contract manufacturing market. Based on service, the Asia-Pacific biopharmaceuticals contract manufacturing market has been segmented into process development, fill and finish operations, analytical and QC studies, and packaging. The process development segment held the largest share of the market in 2020. Based on process development the market is further segmented into downstream processing and upstream processing. In 2020, the downstream processing segment held the largest share Asia-Pacific biopharmaceutical contract manufacturing market. Based on source, the Asia-Pacific biopharmaceuticals contract manufacturing market has been segmented into mammalian and microbial/non-mammalian-based biologics. The mammalian segment held the largest share of the market in 2020. Similarly, based on country, the market is segmented into the Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Japan contributed a substantial share in 2020. 

AbbVie Inc., Ajinomoto Co. Inc, Boehringer Ingelheim International GmbH, General Electric Company, Lonza, MERCK KGAA, Samsung Biologics, THERMO FISHER SCIENTIFIC INC, and WUXI BIOLOGICS are among the leading companies in the Asia-Pacific Biopharmaceutical Contract Manufacturing Market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, WuXi acquires Pfizer’s biosimilar plant in China The sale will also encompass the Pfizer’s plant workforce at the 50,000 sq. meter Hangzhou plant. The plant contains 2000 litre single-use bioreactors and is equipped with filling vials and syringes for shipment in ready-to-use doses.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com